JPMorgan’s Hot Pick: Bristol Myers Squibb
If you’re keeping an eye on the biopharma sector, you might want to pay attention to Bristol Myers Squibb. This stock is making waves as JPMorgan recently crowned it one of their top picks in the industry—a shoutout that’s got everyone buzzing, especially our friend Tim Donovan.
What’s the Buzz About Bristol Myers?
So, here’s the scoop. JPMorgan analysts are really optimistic about Bristol Myers, particularly because of their oral schizophrenia treatment, Cobenfy. According to them, this drug could potentially rake in over $10 billion a year in sales once it goes wider in the market. Amazing, right? Plus, they suggest that the company’s stocks are currently trading at a discount compared to their competitors, making it an attractive option for investors.
Oh, and it gets even better! Bristol Myers has a handful of other promising projects in the pipeline, with more updates expected this year and even into 2026. With healthcare stocks doing relatively well lately—gaining almost 5% while the S&P 500 is down about 4%—it seems like now could be a golden opportunity to dive deeper into this stock.
The Bigger Picture
Now, for the nitty-gritty: healthcare has been the shining star of the S&P 500 this year. Investors seem to be shifting towards “defensive names” as they brace for broader uncertainties in the market. Yet, despite some recent fluctuations, the large-cap biopharma sector remains “under-owned,” according to JPMorgan.
Bristol Myers shares have enjoyed a nice uptick—roughly 4% year-to-date. After all, just last week, we saw a new 52-week high, and some folks even cashed in on profits from those gains. However, there’s been a slight pullback recently, meaning it might be smart to think about re-entering the market at a lower price.
What’s Next?
Tim Donovan shares a positive outlook on Bristol Myers too, especially with two significant Cobenfy readouts set to drop later this year. If they come through big, you can bet analysts will be updating their sales projections and sending those stocks soaring.
Bottom line? Keep an eye on this one. If the price dips and you’re thinking about snagging shares, you might be onto something.
It’s an exciting time to be watching Bristol Myers Squibb closely—could be the start of something big for your investment portfolio!
